ACTEMRA

• tagApproval264 co-mentions · 72 sources
• drugtocilizumab253 co-mentions · 73 sources
• drugTYENNE16 co-mentions · 8 sources
• drugRNS-608 co-mentions · 8 sources
• companyFresenius Kabi USA LLC8 co-mentions · 8 sources
• drugAVTOZMA8 co-mentions · 4 sources
• companyCelltrion Inc4 co-mentions · 4 sources
• companyChugai Pharmaceutical Co Ltd1 co-mentions · 1 sources

Trials studying ACTEMRA

• phase3A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)recruitingn=58
• phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=211
• phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)recruitingn=120
• phase1A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphomarecruitingn=121
• phase2A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myelomanot yet recruitingn=46
• phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)recruitingn=340
• phase3A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphomarecruitingn=182
• phase2A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomarecruitingn=65